Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations
https://www.facingourrisk.org/XRAY/breast-MRI-among-women-with-BRCA-mutations
Full article: https://jamanetwork.com/journals/jamaoncology/fullarticle/2815702
An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What cancer screening recommendations do you suggest based on my mutation and family history?
- What screening guidelines do you follow and why?
- Will my insurance cover a breast screening MRI?
Open Clinical Trials
The following are breast cancer screening or prevention studies enrolling people at high risk for breast cancer.
- NCT04711109: Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P). This study will test the effectiveness of a drug (denosumab) in preventing the development of breast cancer in women with an inherited BRCA1 mutation.
- NCT04067726: Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT). This study is looking at the drug denosumab to learn if it can reduce breast density in high-risk premenopausal women who have dense breasts.
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations. This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in high-risk people.
- NCT02620852: Women Informed to Screen Depending on Measures of Risk (WISDOM) study. The goal of this study is to determine if breast cancer screening can be improved by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all annual approach.
-
NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study is testing a new vaccine to lower the risk of breast cancer in high-risk women with an inherited mutation in BRCA1, BRCA2 or PALB2.
Additional risk-management clinical trials for people at high risk for breast cancer may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.